Levomikon-TFF (Ointment) Instructions for Use
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
ATC Code
D06C (Antibiotics and chemotherapeutic agents in combination with other drugs)
Active Substances
Chloramphenicol (Rec.INN WHO registered)
Dioxomethyltetrahydropyrimidine (Grouping name)
Dosage Form
| Levomikon-TFF | Ointment for external use: jars or tubes 20 g, 25 g, 30 g, 40 g, 50 g, 60 g, 70 g, 80 g, or 100 g |
Dosage Form, Packaging, and Composition
Ointment for external use white or white with a yellowish tint.
| 100 g | |
| Dioxomethyltetrahydropyrimidine (methyluracil) | 4 g |
| Chloramphenicol | 0.75 g |
Excipients: macrogol 1500 – 19.05 g, macrogol 400 – 76.2 g.
20 g – jars (1) – cardboard packs.
25 g – jars (1) – cardboard packs.
30 g – jars (1) – cardboard packs.
40 g – jars (1) – cardboard packs.
50 g – jars (1) – cardboard packs.
60 g – jars (1) – cardboard packs.
70 g – jars (1) – cardboard packs.
80 g – jars (1) – cardboard packs.
100 g – jars (1) – cardboard packs.
20 g – tubes (1) – cardboard packs.
25 g – tubes (1) – cardboard packs.
30 g – tubes (1) – cardboard packs.
40 g – tubes (1) – cardboard packs.
50 g – tubes (1) – cardboard packs.
60 g – tubes (1) – cardboard packs.
70 g – tubes (1) – cardboard packs.
80 g – tubes (1) – cardboard packs.
100 g – tubes (1) – cardboard packs.
Clinical-Pharmacological Group
A drug with antibacterial and tissue regeneration-improving action for external use
Pharmacotherapeutic Group
Antibiotics and antimicrobial agents used in dermatology; antibiotics for topical use; other antibiotics for topical use
Pharmacological Action
A combined medicinal product for topical use, it has anti-inflammatory (dehydrating) and antimicrobial action, and is active against gram-positive and gram-negative microorganisms (staphylococci, Pseudomonas aeruginosa, and Escherichia coli).
It easily penetrates deep into tissues without damaging biological membranes and stimulates regeneration processes.
The antibacterial action is preserved in the presence of pus and necrotic masses. Dioxomethyltetrahydropyrimidine, by normalizing nucleic acid metabolism, stimulates regeneration processes in wounds, tissue growth and granulation maturation, epithelialization, and has an anti-inflammatory (dehydrating) effect.
Indications
Purulent wounds (including those infected with mixed microflora) in the first (purulent-necrotic) phase of the wound process.
ICD codes
| ICD-10 code | Indication |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Apply the ointment topically only.
Use sterile gauze napkins impregnated with the ointment to loosely fill the wound cavity.
Alternatively, introduce the ointment into purulent cavities through a catheter or drainage tube using a syringe.
Apply the dressing once daily or as directed by a physician based on the severity of the wound process.
Change the dressing more frequently if copious exudate causes it to become heavily saturated.
Prior to each application, cleanse the wound surface from residual ointment, pus, and necrotic tissue.
The duration of treatment is determined by the rate of wound cleansing, appearance of granulations, and onset of epithelialization.
Discontinue use and consult a physician if signs of local irritation or allergic reaction develop.
For extensive wounds or prolonged courses of therapy, monitor hematological parameters via clinical blood tests.
Adverse Reactions
Allergic reactions skin rashes.
Contraindications
Children under 1 year of age (in newborns, the biotransformation of chloramphenicol occurs more slowly than in adults); hypersensitivity to the components of the combination.
With caution
Pregnancy, lactation (breastfeeding).
Use in Pregnancy and Lactation
Use during pregnancy is possible if the benefit to the mother outweighs the risk to the fetus.
During lactation, either the use of the medicinal product should be discontinued or breastfeeding should be stopped.
Pediatric Use
Use is contraindicated in children under 1 year of age (in newborns, the biotransformation of chloramphenicol occurs more slowly than in adults).
Special Precautions
When applied to large areas of the skin and during long courses of treatment, a clinical blood test should be performed.
Storage Conditions
Store at 2°C (36°F) to 15°C (59°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer